The effect of loading dose of rosuvastatin on peri-procedural myocardial infarction

Abstract

Abstract Funding Acknowledgements Type of funding sources: None. Objectives The aim of this study is to investigate the effect of rosuvastatin loading dose on peri-procedural myocardial infarction (PPMI) and major adverse cardiac and cerebrovascular events (MACCE) in patients undergoing elective PCI according to their statin use. Background High-dose statin therapy before PCI is thought to reduce the occurrence of PPMI, which is known to be associated with increased mortality and prolonged hospitalization, especially in statin naïve patients. Methods One hundred sixty-five patients were included in the study and divided into two groups as patients already on statin treatment (n:126) and statin naive patients (n:39). Both groups were randomly assigned to high-dose (40 mg) rosuvastatin (n:86) or control group (n:79). The primary endpoint was the incidence of peri-procedural myocardial infarction, and the secondary endpoint was MACCE. Results There was 30 patients (19 in high dose statin group, and 11 in control group) diagnosed as PPMI after percutaneous coronary intervention (PCI). Loading dose of statin therapy did not prohibit occurrence of PPMI. A positive correlation between PPMI and creatinine (r:0.199, p:0.011), lesion complexity (r:0.189, p:0.015) and negative correlation between GFR and PPMI (r:-0.158 p:0,043) was remarkable. Conclusions Pre-procedural administration of high dose rosuvastatin in patients with stable coronary artery disease has failed to decrease PPMI independent of chronic statin use. Table 1. Termβ estimates with standard errorsORp valueConstant (β0)0.656 ± 1.122-0.559Lesion type (β1)1.224 ± 0.4453.4010.006Gfr (β2)-0.031 ± 0.0130.9700.015GFR and lesion type relationships with peri-procedural MI